State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, Hubei, 430072, PR China.
Cancer Lett. 2010 May 28;291(2):158-66. doi: 10.1016/j.canlet.2009.10.011. Epub 2009 Nov 10.
Malignant gliomas are the most common primary brain tumors associated with significant morbidity and mortality. How to target the tumor in situ, and inhibit tumor cell proliferation and invasion is the key for therapy. Gliomas express a glioma-specific chloride ion channel that is sensitive to toxins including BmKCT. In the current study, the inhibitory effect of BmKCT on glioma growth was observed in vivo using the glioma/SD rat model. Furthermore, BmKCT prevented the metastasis of glioma cells in vivo. Moreover, biodistribution experiments with (l3l)I-labeled or Cy5.5-conjugated BmKCT revealed that BmKCT selectively targeted the glioma in situ. Our data suggest that BmKCT could be exploited as a potential therapeutic for glioma diagnosis and therapy.
恶性脑胶质瘤是最常见的原发性脑肿瘤，与显著的发病率和死亡率相关。如何在原位靶向肿瘤，并抑制肿瘤细胞的增殖和侵袭，是治疗的关键。脑胶质瘤表达一种对毒素（包括 BmKCT）敏感的胶质瘤特异性氯离子通道。在本研究中，我们使用脑胶质瘤/SD 大鼠模型观察了 BmKCT 对体内脑胶质瘤生长的抑制作用。此外，BmKCT 还能防止脑胶质瘤细胞的体内转移。此外，用 (l3l)I 标记或 Cy5.5 偶联的 BmKCT 进行的生物分布实验表明，BmKCT 选择性地靶向原位脑胶质瘤。我们的数据表明，BmKCT 可以作为一种潜在的治疗脑胶质瘤的诊断和治疗方法。
